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Abstract
Aim: To evaluate the efficacy of the Portuguese version of the metacognitive training 
(MCT) programme for schizophrenia and its effects on psychotic symptoms, insight 
into the disorder and functionality.
Design: This is a randomized controlled trial that will be undertaken in six psychiatric 
institutions in Portugal.
Methods: This study was approved in March 2019. The sample will consist of people 
with schizophrenia. The evaluation instruments will include sociodemographic and 
clinical questionnaires, the Psychotic Symptom Rating Scales, the Beck Cognitive 
Insight Scale, the World Health Disability Assessment Schedule, and the Personal 
and Social Performance Scale, applied to both groups at three different times. In the 
experimental group, the eight MCT modules will be applied over 4 weeks.
Discussion: It is expected that at the end of the programme, the experimental group 
will have reduced severity of psychotic symptoms and improved insight into the dis-
ease and functionality.
Impact: Schizophrenia is a severe mental disorder that, in most cases, leads to the 
deterioration of cognitive and social functioning as a result of psychotic symptoms. 
     |  357de PINHO et al.
1  | INTRODUC TION
Mental diseases are responsible for more than 12% of the global 
burden of disease worldwide and 23% in developed countries. Five 
of the top ten causes of long‐term disability and psychosocial de-
pendence are mental diseases: unipolar depression (11.8%), alcohol 
problems (3.3%), schizophrenia (2.8%), bipolar disorders (2.4%), and 
dementia (1.6%); (Xavier, Baptista, Mendes, Magalhães, & Caldas‐
de‐Almeida, 2013 quoted in Carvalho, 2013).
Schizophrenia is a severe mental disorder characterized by 
psychotic symptoms (positive and negative symptoms). Delusions 
(thought changes), hallucinations (perception changes), and disor-
ganization of thinking and behaviour are considered positive symp-
toms. The most frequent negative symptoms are avolition, decrease 
in emotional expression, alogia, anhedonia, and social isolation 
(American Psychiatric Association, 2014).
Delusions and hallucinations are two psychotic symptoms that 
characterize schizophrenia. Over time, this disease usually causes 
cognitive and social dysfunction. In many cases, treatment of schizo-
phrenia with medication alone is still a reality. In addition, there are 
not enough resources for this condition in the community and the 
implementation of psychotherapeutic strategies for psychosocial re-
habilitation is scarce. Thus, it is urgent that we develop more effec-
tive care management strategies in response to this problem.
1.1 | Background
In most cases, the exclusive treatment of schizophrenia with medica-
tion is not very effective and is insufficient for patient rehabilitation. 
Additionally, poor insight and low adherence to treatment require 
the implementation of psychotherapies that complement treatment 
with neuroleptics. In this sense, cognitive‐behavioural therapy ap-
proaches and family interventions have been shown to be a funda-
mental complement to psychopharmacology (Pfammatter, Andres 
& Brenner, 2012; Townsend, 2011; Wykes, Steel, Everitt, & Tarrier, 
2008).
Metacognitive training (MCT) for psychosis is a cognitive‐be-
havioural therapy registered by Steffen Moritz in 2007. Some recent 
studies have demonstrated that MCT is beneficial for people with 
schizophrenia and lowers the severity of delusions, as demonstrated 
by recent meta‐analyses (Eichner & Berna, 2016; Jiang, Zhang, 
Zhipei, Wei, & Chunbo, 2015; Liu, Tang, Hung, Tsai, & Lin, 2018; van 
Oosterhout et al., 2016). However, these meta‐analyses showed 
different results. While the results of Liu et al. (2018) and Eichner 
and Berna (2016) demonstrated that after MCT application, the se-
verity of delusion decreased immediately, meta‐analyses by Jiang el 
al. (2015) and van Oosterhout et al. (2016) showed that delusions 
decreased only over time. Furthermore, the positive effect of MCT 
at 6 months post‐intervention was demonstrated only in the most 
recent meta‐analysis (Liu et al., 2018). Thus, more studies are neces-
sary to prove the efficacy of MCT.
The four meta‐analyses presented studied the effects of MCT 
in 12 countries: Australia, England, Finland, France, Germany, 
Hong Kong, India, Ireland, the Netherlands, Poland, Portugal, and 
Switzerland. In Portugal, Rocha and Queirós (2013) studied the pre-
liminary efficacy of Metacognitive and Social Cognition Training 
(MSCT) in schizophrenia with 18 sessions. In this study, MSCT had 
no effect on positive symptoms, contrary to expectations (Rocha 
& Queirós, 2013). MCT has not yet been validated in Portugal and 
studies are needed to prove its efficacy in the Portuguese popula-
tion. Therefore, to evaluate the efficacy of this programme in people 
with schizophrenia, a randomized controlled trial will be conducted 
using the protocol presented in this article. MCT will be applied by 
mental health nurses. The research question of this study is as fol-
lows: ‘Is metacognitive training in people with schizophrenia effec-




The aim of this study is to evaluate the efficacy of a metacognitive 
group training in people with schizophrenia and its effects on psy-
chotic symptoms, insight into the disorder and functionality. The hy-
potheses to be validated in this trial are as follows:
• Compared with the control participants, the people with schizo-
phrenia who join the experimental group and participate in the 
MCT programme will have reduced severity of psychotic symp-
toms, will present better insight into their disease, and will have 
improved functionality on completion of the programme;
• In the MCT programme participants, psychotic symptoms will be 
reduced at the end of the programme and at follow‐up (3 months 
later) and their consciousness of the disease and functionality will 
improve.
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2.2 | Design/methodology
2.2.1 | Study design
The MCT programme groups were designed for a randomized con-
trolled trial. The sample will be selected by a probabilistic method 
and participants will be randomly distributed into one of two groups 
(experimental or control). Taking into account the evolution of schiz-
ophrenia and the possible influence of sociodemographic and clini-
cal characteristics, the stratified random sampling method will be 
applied.
All procedures shall be in accordance with the CONSORT 
(Consolidated Standards of Reporting Trials) guidelines and fol-
low four phases: enrolment, intervention allocation, follow‐up, and 
data analysis. The follow‐up will be undertaken 3 months after the 
programme. The trial has been registered at ClinicalTrials.gov (ID 
NCT03891186).
2.2.2 | Participants
The population of this study will be composed of people with schiz-
ophrenia who attend psychosocial rehabilitation programmes or 
socio‐occupational forums in psychiatric institutions in Portugal.
Inclusion criteria
Age between 18–65 years; diagnosis of schizophrenia evaluated by 
a psychiatric assistant; and no changes in neuroleptic medication 
within for 4 months before the programme.
Exclusion criteria
Substance dependence; very severe psychotic symptoms that im-
pede understanding of the objectives of the sessions; and changes 
in neuroleptic medication within 4 months before the programme.
2.2.3 | Randomization and blinding
Eligible participants will be recruited by the researchers in col-
laboration with a multidisciplinary team from each institution. A 
baseline assessment will be carried out and the instruments will be 
applied after informed consent from the participants. Participants 
will be randomly allocated to either the MCT (experimental group) 
or the control group. The control group will not participate in the 
MCT programme. In both groups, treatment will be maintained as 
usual. Participants will be stratified by educational level, duration of 
mental disorder, and type of treatment. All participants will be re‐as-
sessed at the end of the programme and 3 months after completion. 
The programme will be applied over 4 weeks (two sessions per week) 
by a mental health nurse at the institution. The instruments will be 
applied by the same researcher before and after the programme and 
at follow‐up. This researcher will not know to which group the par-
ticipants belong. Thus, the researcher that applies the instruments 
will be blinded (Figure 1).
2.2.4 | Sample size determination
Assuming an effect size like those of previous studies (Lam et al., 
2015; Moritz et al., 2013) and considering α = 0.05 and power = 0.80, 
a total sample size of 36 (18 participants per condition) could be 
considered to detect an effect in the primary outcome (partial eta 
square = 0.04). Sample size calculation was performed with G*Power 
(Erdfelder, Faul, & Buchner, 1996). Considering a dropout of 10%, we 
aimed to include 40 participants.
2.2.5 | Study intervention
Treatment as usual
All participants will continue to receive treatment as usual (TAU) 
at their institution. TAU consists of psychiatric and psychosocial 
treatment by a multidisciplinary team, including mental health psy-
chiatric nurses, psychiatrists, psychologists, social workers, and 
occupational therapists. TAU includes community treatment, day 
hospital, and hospital admission and involves antipsychotic medica-
tion, psychosocial rehabilitation, socialization groups, and psycho‐
educational and therapy groups. In this way, procedural ethics will 
be maintained. The control group will not participate in the MCT 
programme.
Metacognitive training for psychosis
Metacognitive training is a cognitive approach to the treat-
ment of positive symptoms in psychosis that has been trans-
lated into 37 languages. MCT was developed by Moritz and 
colleagues (Moritz & Woodward, 2007; Moritz, Vitzthum, Randjbar, 
Veckenstedt, & Woodward, 2010; Moritz, Woodward, & Rocha, 
2010) and all information about this programme is available at 
https ://clini cal‐neuro psych ology.de/metac ognit ive_train ing‐psych 
osis/. The most recent Portuguese version was concluded in 2017 
(Portuguese version 6.3; Moritz, Woodward, Hauschildt & Rocha, 
2017). Specific terms were adapted to Portugal, but the examples 
were kept the same for consistency across countries. However, the 
intervention and examples can be tailored by the therapist to meet 
specific group needs.
Metacognitive training is composed of eight modules referring 
to common cognitive issues and biases in solving problems in schizo-
phrenia. The topics of MCT include the following: attribution blam-
ing and taking credit (module 1), jumping to conclusions (modules 2 
& 7), changing beliefs (module 3), deficits in theory of mind and so-
cial cognition (modules 4 and 6), overconfidence in (memory) errors 
(module 5), and depression and low self‐esteem (module 8).
The aim of the sessions is to convey knowledge about cognitive 
distortions, such as false beliefs and delusions and helping patients to 
reflect critically with exercises and acquire new problem‐solving strat-
egies. Each session lasts 45–60 min and follows a protocol defined in 
the ‘Metacognitive Training for Psychosis (MCT)’ manual. The materials 
used in MCT are PowerPoint slides, videos, homework exercises, and 
yellow and red cards. These materials are available at www.uke.de/mkt.
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The MCT for Schizophrenia programme will be applied to the ex-
perimental group by mental health and psychiatry specialist nurses 
with professional experience in the care of people with schizophre-
nia. A practical course on MCT was implemented and all mental 
health and psychiatry nurses received training on the application of 
the MCT programme. It will be applied in two sessions per week for 
a total of eight sessions.
Metacognitive training will be applied face‐to‐face in groups in 
a quiet room of the psychiatric institution to which the group be-
longs. If a participant's neuroleptic medication is changed during the 
course of the programme, they will be excluded from the study. To 
improve adherence to MCT, the sessions will be applied during the 
period of usual treatment.
2.2.6 | Data collection and outcome measures
The instruments will be applied to all participants in the study 
through an interview at the three assessment times. To charac-
terize the sample, sociodemographic, and clinical data will be col-
lected (age, gender, marital status, cohabitation, educational level, 
professional/employment status, duration of mental disorder, num-
ber of psychiatric hospitalizations, medication, type of treatment, 
and substance use). These data will be collected before the begin-
ning of the programme for all participants.
PSYRATS – Psychotic symptom rating scales
This instrument is a structured interview that provides a detailed 
measurement of delusions and hallucinations. The PSYRATS have 
17 items and two subscales: one subscale assesses delusions (6 
items) and the other assesses hallucinations (11 items). Each item has 
a classification of five points (0–4). It was developed by Haddock, 
McCarron, Tarrier, and Faragher (1999) (validated for the Portuguese 
population by Telles‐Correia et al. (2017)).
BCIS – Beck cognitive insight scale
This scale has 15 items and is a self‐response questionnaire de-
veloped by Beck, Baruch, Balter, Steer, and Warman (2004) that 
evaluates consciousness of the illness. (It is in the process of vali-
dation for the Portuguese population by the researchers of this 
study.)






























appraisal of the 
interventions]
X X
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WHODAS 2.0 – World health disability assessment schedule
This instrument evaluates functionality levels and was developed by 
the WHO. It has 12 items and is a self‐response questionnaire (vali-
dated for the Portuguese population by Moreira, Alvarelhão, Silva, 
Costa, and Queirós (2015)).
PSP – Personal and social performance scale
This scale was developed by Morosini, Magliano, Brambilla, Ugolini, 
and Pioli (2000) and assesses patients’ social functioning with regard 
to four main areas: socially useful activities, personal and social rela-
tionships, self‐care, and disturbing and aggressive behaviours (vali-
dated for the Portuguese population by Brissos et al., 2012).
The PSYRATS, BCIS, WHODAS 2.0, and PSP will be applied to 
both groups before the first session of MCT and a week after the eight 
sessions. Three months later, these instruments will be reapplied for 
follow‐up evaluation in both the groups. These evaluations will be con-
ducted by a different person than the one who applied the MCT pro-
gramme to avoid bias and they will be applied in person.
Subjective appraisal of the interventions
In the pilot study, at the end of the MCT for Schizophrenia and at 
follow‐up, an anonymous questionnaire will be conducted to assess 
acceptance, feasibility, and subjective efficacy of the interventions. 
This instrument was applied in previous trials (Moritz, Kerstan, et al., 
2011; Moritz et al., 2013; Moritz, Veckenstedt, Randjbar, Vitzthum, 
& Woodward, 2011; Moritz & Woodward, 2007) and it will be com-
pleted only by the experimental group. The outcome measures are 
listed in Table 1.
2.2.7 | Data analysis
The data will be analysed using Statistical Package for Social Sciences 
software (SPSS®) version 24.0 for Windows. Descriptive analysis will 
be used to characterize the sample. To compare the results in both 
groups and to compare the results of the PSYRATS, BCIS, WHODAS, 
and PSP at the three application times, statistical inference will be 
used.
2.3 | Ethical considerations and dissemination
Approval was obtained from all the institutions’ ethics commit-
tees. All participants will be informed of the study objectives, 
methodology, benefits, and possible risks. They will sign the writ-
ten informed consent required for this study. Participant confi-
dentiality will be maintained throughout all study procedures. 
Participants will be informed that they may withdraw their partici-
pation at any time without penalty. Only members of the research 
team and health professionals that care for the participants have 
access to participant data. These data will be destroyed at the end 
of the study.
Any modifications to the protocol that may have an impact on 
the implementation of the study, for example, changes in study 
design, study objectives, and study procedures, will be revised by 
independent researchers and will be communicated to the ethical 
committees. The results of the study will be disseminated through 
oral communications in congresses, publication in journals and 
posters.
2.4 | Validity and reliability/rigour
Variables such as educational level, duration of mental disorder, and 
type of treatment may influence the results of this study. The pro-
posed stratified random sampling method in this study is intended to 
minimize confounding bias.
3  | DISCUSSION
In some countries, previous studies have proved the efficacy of 
MCT and its ability to reduce positive symptoms (Aghotor, Pfueller, 
Moritz, Weisbrod, & Roesch‐Ely, 2010; Andreou et al., 2017; Briki et 
al., 2014; Favrod et al., 2014; Kumar et al., 2010; Moritz et al., 2013; 
So et al., 2015). However, other studies did not find this efficacy 
in reducing positive symptoms (Gaweda, Krezołek, Olbrys, Turska, 
& Kokoszka, 2015; van Oosterhout et al., 2014). More studies are 
needed to accurately prove the efficacy of MCT.
With respect to cognitive insight, a randomized control trial with 
a sample of 80 people with schizophrenia showed significant im-
provements in cognitive insight in the experimental group (Lam et al., 
2015). However, in another randomized control trial with a sample 
of 154 people with schizophrenia, MCT was not more efficacious in 
terms of cognitive insight (van Oosterhout et al., 2014). Both studies 
used the BCIS to evaluate cognitive insight. The efficacy of the MCT 
programme for people with schizophrenia has not yet been studied 









Sociodemographic and clinical data Experimental group and control group X   
PSYRATS Experimental group and control group X X X
BCIS Experimental group and control group X X X
Subjective appraisal of the interventions Experimental group of the pilot study  X X
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in the Portuguese population and thus the development of the pres-
ent trial is paramount.
The most recent meta‐analysis of randomized control trials that 
used the MCT programme for people with schizophrenia concluded 
that for MCT to be successful in the future, a better understand-
ing of the mechanism and factors that improve the efficacy of MCT 
may be helpful (Liu et al., 2018). The greatest challenges expected 
in the development of this trial are related to the potential of peo-
ple with schizophrenia to not consent to participate in the research 
due to the low adherence to treatment and poor insight into disease 
characteristic of people with this disease. This could influence the 
sample size. To minimize this potential constraint, six psychiatric in-
stitutions were chosen to collect data.
It is expected that the results of this trial will validate the Portuguese 
version of MCT and prove its efficacy in reducing the severity of psy-
chotic symptoms, and in improving consciousness of the illness and 
functioning in people with schizophrenia. The results of this trial are 
expected to allow future implementation of the MCT programme by 
mental health and psychiatry specialist nurses and other mental health 
professionals in various mental health institutions.
3.1 | Limitations
In this study, the setting is confined to six institutions to Portugal, 
which will limit the generalizability of the results to other countries.
4  | CONCLUSION
It has been proven that the best treatment for schizophrenia is the 
combination of psychopharmacology and cognitive‐behavioural 
therapy. MCT intends to contribute to the psychosocial rehabilita-
tion of people with schizophrenia used by mental health nurses or 
other mental health professionals. The trial illustrated in this protocol 
intends to assess the efficacy of MCT in the Portuguese population.
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